secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2024-09-30T23:59:59+00:00
Accession:  0001140361-24-042352
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acasti Pharma shareholders approve continuance to BC, domestication to Delaware, and 2024 equity plan
--------------------------------------------------------------------------------

- Shareholders approved continuance from Quebec to British Columbia (5,874,491 For, 71,931 Against, 8,683 Abstain).
- Shareholders approved domestication from British Columbia to Delaware (5,891,584 For, 54,366 Against, 9,155 Abstain).
- Shareholders approved the 2024 Equity Incentive Plan (5,832,903 For, 86,289 Against, 35,913 Abstain).
- All five director nominees were elected; KPMG ratified as auditor (7,055,362 For).
- Advisory vote on named executive officer compensation passed (5,685,429 For, 98,138 Against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036124042352/0001140361-24-042352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036124042352/ef20036442_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-042352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer